Tirzepatide

Tirzepatide's core innovation is dual agonism of the GIP and GLP-1 receptors. GLP-1 (glucagon-like peptide-1) suppresses appetite via hypothalamic receptors, slows gastric emptying, and stimulates insulin secretion. GIP (glucose-dependent insulinotropic polypeptide) is a separate incretin hormone that works through distinct receptors in the brain, pancreas, and adipose tissue. GIP receptors in the hypothalamus regulate energy balance and food intake through different neuronal populations than GLP-1. When both pathways are activated simultaneously, the appetite-suppressing effect is amplified beyond the sum of each alone.

At the molecular level, tirzepatide is a 39-amino acid peptide based on the GIP sequence but engineered to also activate the GLP-1 receptor. It has approximately 5x higher affinity for the GIP receptor than the GLP-1 receptor, making it a biased dual agonist. A C-20 fatty di-acid chain attached via a linker enables albumin binding and extends the half-life to approximately 5 days, suitable for once-weekly injection.

The GIP receptor activation provides additional metabolic benefits beyond GLP-1: direct effects on adipose tissue (promoting fat metabolism and reducing fat storage), enhanced beta-cell function and survival in the pancreas, and bone-protective effects (GIP signaling reduces bone resorption). This multi-system activation explains why tirzepatide produces greater body weight reduction, better glycemic control, and improved lipid profiles compared to GLP-1 monotherapy.

Research suggests the GIP component may also reduce the severity of gastrointestinal side effects compared to pure GLP-1 agonists at equivalent appetite-suppressing doses. GIP modulates gastric motility differently than GLP-1, and the dual activation may produce a more tolerable balance of gastric emptying modulation. This hypothesis is supported by the lower nausea rates seen in SURMOUNT trials at doses producing greater weight loss than semaglutide.

SURMOUNT-1 (n=2,539) is the landmark obesity trial. At 72 weeks with the 15mg dose: mean weight loss was 22.5% of body weight. 96% of patients achieved ≥5% weight loss. 63% achieved ≥20% weight loss. These numbers exceeded any previously published weight loss drug trial. Published in the New England Journal of Medicine in July 2022, SURMOUNT-1 established tirzepatide as the most effective approved anti-obesity medication.

SURMOUNT-2 (n=938) studied tirzepatide specifically in patients with type 2 diabetes and obesity, showing 14.7% mean weight loss at 15mg — remarkable for a diabetes population where weight loss is typically blunted. SURMOUNT-3 (n=579) combined tirzepatide with intensive lifestyle intervention, achieving a combined 26.6% mean weight loss. SURMOUNT-4 (n=783) was a withdrawal/re-randomization study showing that switching from tirzepatide to placebo resulted in substantial weight regain, while continuing treatment maintained the loss.

The SURPASS program studied tirzepatide for type 2 diabetes specifically. SURPASS-2 (n=1,879) directly compared tirzepatide to semaglutide 1mg and showed tirzepatide's superiority: greater HbA1c reduction (2.07% vs 1.86%) and greater weight loss (12.4kg vs 6.2kg) at 40 weeks. This head-to-head comparison was definitive evidence of tirzepatide's superiority over the GLP-1 standard of care.

SURPASS-CVOT, the cardiovascular outcomes trial for tirzepatide, is ongoing. Based on semaglutide's SELECT trial results, cardiovascular benefit is expected but has not yet been formally demonstrated for tirzepatide. This remains a gap in tirzepatide's evidence base compared to semaglutide.

Tirzepatide for weight management (Zepbound) follows a dose escalation: Weeks 1-4: 2.5mg/week → Weeks 5-8: 5mg/week → subsequent escalations in 2.5mg increments every 4 weeks to a maximum of 15mg/week. Not all patients need to reach 15mg — some achieve satisfactory results at 5mg or 10mg with fewer side effects. The decision to escalate should be based on weight loss trajectory and tolerability.

For type 2 diabetes (Mounjaro), the same escalation schedule applies but may be driven by glycemic targets rather than weight loss goals. Some patients achieve HbA1c targets at lower doses.

In the research peptide context, tirzepatide is available as a lyophilized powder. Reconstitution and dosing follows the same principles as semaglutide but with different dose ranges. The starting dose is higher (2.5mg vs 0.25mg for semaglutide) because tirzepatide's potency per milligram is different due to its dual receptor activation profile.

Administration is subcutaneous injection once weekly. Injection sites include abdomen, thigh, or upper arm, with rotation between sites. Tirzepatide should be stored refrigerated (2-8°C) and protected from light. The multi-dose pen devices (Mounjaro/Zepbound) can be stored at room temperature for up to 21 days after first use.

Tirzepatide's GI side effect rates at comparable weight loss levels may actually be lower than semaglutide's, though direct comparison is complicated by different dosing schedules. In SURMOUNT-1: nausea 31% at 15mg (vs 44% for semaglutide in STEP 1), vomiting 13% (vs 25%), diarrhea 23% (vs 30%), constipation 12% (vs 24%). These lower rates may be partially attributed to the GIP component's moderating effect on gastric motility.

The same serious adverse event warnings apply as for semaglutide: pancreatitis risk, gallbladder disease with rapid weight loss, thyroid C-cell tumor black box warning from rodent studies, and contraindication in MEN2/medullary thyroid carcinoma. Injection site reactions are infrequent and mild.

Lean mass loss with tirzepatide follows a similar pattern to semaglutide: approximately 33-39% of total weight lost is lean mass. The absolute lean mass loss may be greater than semaglutide simply because total weight loss is greater. The same mitigation strategies apply: resistance training, high protein intake, and potential GH peptide adjuncts.

A unique consideration for tirzepatide is its GIP receptor activation in bone tissue. GIP signaling has bone-protective properties, and there is theoretical evidence that tirzepatide may cause less bone mineral density loss during weight reduction compared to pure GLP-1 agonists. This has not been confirmed in dedicated bone density studies but is being investigated.